Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S379-S383

  Wong, Gary ^a,b   Richardson, Jason S ^a   Pillet, S ^a   Racine, Trina ^a   Patel, Ami ^a,b   Soule, Geoff ^a   Ennis, Jane ^d   Turner, Jeffrey ^d   Qiu, Xiangguo ^a,b   Kobinger, Gary P ^a,b,c,e  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Department of Medical Microbiology ^*  (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Defyrus Inc   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adenovirus; Ebola; nonhuman primates; post exposure; vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; EBOLA VACCINE; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZAIRE EBOLA VIRUS GLYCOPROTEIN; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; HUMAN ADENOVIRUS 5; INTERFERON PRODUCTION; MACACA FASCICULARIS; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RHESUS MONKEY; VIREMIA; ZAIRE EBOLAVIRUS; ANIMAL; EBOLAVIRUS; GENE VECTOR; HUMAN; HUMAN ADENOVIRUS C; HUMAN ADENOVIRUS INFECTION; IMMUNOLOGY; PROCEDURES; VACCINATION; VIROLOGY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; VACCINATION;

EID: 84941805575     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv102     Document Type: Article

References (13)

1. World Health Organization. Ebola Situation Report-11 March 2015, 2015. Available at: http://apps.who.int/ebola/current-situation/ebolasituation-report-11-march-2015. Accessed 12 March 2015.
2. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
3. Butler D, Morello L. Ebola by the numbers: The size, spread and cost of an outbreak. Nature 2014; 514:284-5.
4. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014; 13:521-31.
5. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
6. Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol 2014; 22:456-63.
7. Choi JH, Jonsson-Schmunk K, Qiu X, et al. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Mol Pharm 2014; 4:1-8.
8. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7.
9. Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013; 87:3668-77.
10. Richardson JS, Wong G, Pillet S, et al. Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J Bioterror Biodef 2011; S1:1-8.
11. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4:e5308.
12. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77:7539-44.
13. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4:158ra46.